Top Markets
Coin of the day
Bioceltix S.a. Bioceltix S.a.

Bioceltix S.a.

BCX
Rank in Stocks #20646
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals... Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.
Share Price
$22.66
Market Cap
$125.37M
Change (1 day)
0.63%
Change (1 year)
-21.46%
Country
PL
Trade Bioceltix S.a. (BCX)

Category

Earnings for Bioceltix S.a. (BCX)
Earnings in 2026 TTM: 0
According to Bioceltix S.a. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Bioceltix S.a. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH